seqWell Launches Loaded-transposase Portfolio to Support Expanding Use of NGS-based Gene Editing Analysis Methods [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Editas Medicine, Inc. (EDIT)
Last editas medicine, inc. earnings: 2/26 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.editasmedicine.com
Company Research
Source: Yahoo! Finance
BEVERLY, Mass., June 26, 2024 BUSINESS WIRE seqWell , a global provider of genomic library and multiplexing workflow solutions, today announced the launch of their new portfolio of Tagify loaded-transposase reagents, including Tagify i5 UMI adapter-loaded Tn5 . In addition, seqWell will offer loading of transposases with customer-specified oligonucleotides, including loading of their high-performance TnX transposase The Tagify portfolio provides a commercial source of fully quality-controlled, loaded transposases with a defined level of enzyme activity and payload verification. This eliminates the need of laboratories to purify, load, and characterize the final loaded transposase prior to use in their assays, freeing up laboratory resources and reducing a source of assay-to-assay variability. "Assays to define the genome-wide on- and off-target activity of genome editors are important for both biomedical research and therapeutics," said Shengdar Tsai, Ph.D , Associate Member, Dep
Show less
Read more
Impact Snapshot
Event Time:
EDIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDIT alerts
High impacting Editas Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
EDIT
News
- Editas Medicine, Inc. (NASDAQ: EDIT) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $12.00 price target on the stock.MarketBeat
- Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress [Yahoo! Finance]Yahoo! Finance
- Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress [Yahoo! Finance]Yahoo! Finance
- Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual CongressGlobeNewswire
- Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual CongressGlobeNewswire
EDIT
Earnings
- 5/8/24 - Miss
EDIT
Sec Filings
- 6/27/24 - Form 8-K
- 6/14/24 - Form 8-K
- 6/6/24 - Form 4
- EDIT's page on the SEC website